Pulse Biosciences Inc.

3 days ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Stifel 2026 Healthcare Conference in New York, NY. Pulse Biosciences' Management is scheduled to present on Thursday, November 12, at 11:20 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and P.

11 days ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in l.

19 days ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to.

25 days ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York. A presentation at the Symposium will feature preclinical applications of two nPulse prototype endoc.

2 months ago · fool.com

An analyst initiated coverage with an unambiguous buy recommendation. He feels that one market in particular is ripe for disruption by the company.

3 months ago · seekingalpha.com

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

3 months ago · marketbeat.com

Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.

3 months ago · zacks.com

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.

3 months ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim.

3 months ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Pulse Biosciences' Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presenta.